Ushiroyama T, Ikeda A, Ueki M
Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.
J Med. 2004;35(1-6):151-62.
To evaluate the efficacy of the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine in treating depression in the menopausal transition and to compare their efficacy, safety, side-effect profiles and drug compliance. One hundred and five perimenopausal patients (51.3 +/- 2.5 yr of age) were randomly assigned to receive a dosage of 50 mg/day of fluvoxamine (n=53) or 20 mg/day of paroxetine (n=52). The visual analog scale (VAS), Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores were evaluated before and after 3 months of therapy in the two groups of women. Significant reduction in HAM-D and HAM-A scores was observed in both groups of women, without significant difference between the two groups. VAS score in the fluvoxamine group (-62.6 +/- 5.2%) was significantly lower than that in the paroxetine group (-51.1 +/- 4.3%) (P < 0.0001). Although fluvoxamine compares favourably with paroxetine in rate of reduction of VAS score, this study suggests that both SSRIs are effective for and tolerated in depressed perimenopausal outpatients.
评估选择性5-羟色胺再摄取抑制剂（SSRI）氟伏沙明和帕罗西汀治疗围绝经期抑郁症的疗效，并比较它们的疗效、安全性、副作用特征及药物依从性。105例围绝经期患者（年龄51.3±2.5岁）被随机分为两组，分别接受每日50mg氟伏沙明（n = 53）或每日20mg帕罗西汀（n = 52）治疗。在两组女性治疗3个月前后，评估视觉模拟量表（VAS）、汉密尔顿抑郁量表（HAM-D）和汉密尔顿焦虑量表（HAM-A）得分。两组女性的HAM-D和HAM-A得分均显著降低，两组间无显著差异。氟伏沙明组的VAS得分（-62.6±5.2%）显著低于帕罗西汀组（-51.1±4.3%）（P < 0.0001）。尽管在降低VAS得分率方面氟伏沙明优于帕罗西汀，但本研究表明两种SSRI对围绝经期门诊抑郁症患者均有效且耐受性良好。
